Mekonnen Endalkachew, Workicho Abdulhalik, Hussein Nezif, Feyera Teka
Department of Medicine, College of Medicine and Health Science, Jigjiga University, Jigjiga, Ethiopia.
Department of Epidemiology, College of Health and Medical Sciences, Jimma University, Jimma, Ethiopia.
BMC Res Notes. 2018 Jun 5;11(1):351. doi: 10.1186/s13104-018-3470-y.
This retrospective cohort study is aimed to assess reasons and predictors of regimen change from initial highly active antiretroviral therapy among 1533 Human Immunodeficiency virus-infected adult patients at the Jimma University Tertiary Hospital.
One in two (47.7%) adults changed their antiretroviral therapy regimen. Patients who were above the primary level of education [Hazard ratio (HR) 1.241 (95% CI 1.070-1.440)] and with human immunodeficiency virus/tuberculosis co-infection [HR 1.405 (95% CI 1.156-1.708)] had the higher risk of regimen change than their comparator. Individuals on Efavirenz [HR 0.675 (95% CI 0.553-0.825)] and non-stavudine [HR 0.494 (95% CI 0.406-0.601)] based regimens had lower risk of regimen change.
这项回顾性队列研究旨在评估吉姆马大学三级医院1533例感染人类免疫缺陷病毒的成年患者从初始高效抗逆转录病毒治疗方案变更的原因及预测因素。
二分之一(47.7%)的成年人更改了他们的抗逆转录病毒治疗方案。接受过小学以上教育的患者[风险比(HR)1.241(95%置信区间1.070 - 1.440)]以及合并人类免疫缺陷病毒/结核病感染的患者[HR 1.405(95%置信区间1.156 - 1.708)]比对照者有更高的方案变更风险。基于依非韦伦[HR 0.675(95%置信区间0.553 - 0.825)]和非司他夫定[HR 0.494(95%置信区间0.406 - 0.601)]的治疗方案的个体方案变更风险较低。